Izraēla - ivrits - Ministry of Health

novartis israel ltd - ciclosporin - קפסולות - ciclosporin 100 mg - cyclosporin - cyclosporin - prophylaxis of organ rejection in kidney liver heart allogenic transplants in conjunction with corticosteroids. may also be used in the treatment of chronic rejection in patients previously treated with other immuno-suppressive agents. bone marrow transplantation. endogenous uveitis. severe psoriasis above age 16 that did not respond to other treatment. atopic dermatitis in adults only up to 8 weeks for severe cases in which conventional therapy is ineffective or inappropriate. rheumatoid arthritis: severe cases in which standard treatments are ineffective or inappropriate. nephrotic syndrom type mcd (minimal change disease) in cases where conventional therapy has failed.

Izraēla - ivrits - Ministry of Health

novartis israel ltd - deferoxamine mesylate - אבקה להמסה להזרקה\אינפוזיה - deferoxamine mesylate 0.5 g/vial - deferoxamine - deferoxamine - treatment of chronic iron overload e.g.: transfusional haemosiderosis especially in thalassaemia major sideroblastic anaemia autoimmune haemolytic anaemia and other chronic anaemias idiopathic (primary) haemochromatosis in patients in whom concomitant disorders ( e.g. severe anaemia cardiac disease hypoproteinaemia) preclude phlebotomy iron overload associated with porphyria cutanea tarda. treatment of acute iron poisoning. treatment of chronic aluminium overload in patients with terminal renal failure (under maintenance dialysis) with: aluminium-related bone disease and/or dialysis encephalopathy and/or aluminium-related anaemia. diagnosis of iron overload.

Izraēla - ivrits - Ministry of Health

novartis israel ltd - deferoxamine mesylate - אבקה להמסה להזרקה\אינפוזיה - deferoxamine mesylate 0.5 g/vial - deferoxamine

Izraēla - ivrits - Ministry of Health

novartis israel ltd - deferoxamine mesylate - אבקה להמסה להזרקה\אינפוזיה - deferoxamine mesylate 0.5 g/vial - deferoxamine

Izraēla - ivrits - Ministry of Health

boehringer ingelheim israel ltd. - empagliflozin - טבליות מצופות פילם - empagliflozin 10 mg - linagliptin and empagliflozin

Izraēla - ivrits - Ministry of Health

boehringer ingelheim israel ltd. - empagliflozin - טבליות מצופות פילם - empagliflozin 25 mg - linagliptin and empagliflozin

Izraēla - ivrits - Ministry of Health

bayer israel ltd - norethisterone acetate - טבליה - norethisterone acetate 5 mg - norethisterone - norethisterone - oral progestron for: dysfunctional bleeding, primary and secondary amenorrhea, premenstrual syndrome, timing of mensturation and endometriosis.

Izraēla - ivrits - Ministry of Health

padagis israel agencies ltd, israel - labetalol hydrochloride - טבליה - labetalol hydrochloride 100 mg - labetalol - labetalol - treatment of all grades of hypertension (mild, moderate and severe) when oral antihypertensive therapy is desirable.

Izraēla - ivrits - Ministry of Health

merck sharp & dohme israel ltd - peginterferon alfa 2b 80 mcg / 0.5 ml - powder for solution for injection - interferon alfa-2b - peg- intron is indicated for the treatment of adult patients with histologically proven chronic hepatitis c who have elevated transaminases without liver decompensation and who are positive for serum hcv-rna or anti-hcv including naive patients with clinically stable hiv coinfection. the best way to use peg- intron in this indication is in combination with ribavirin. this combination is indicated in naive patients including patients with clinically stable hiv co-infection and in patients who have failed previous treatment with interferon alpha (pegylated or nonpegylated ) and ribavirin combination therapy or interferon alpha monotherapy. interferon monotherapy including peg-intron is indicated mainly in case of intolerance or contraindication to ribavirin. please refer also to the ribavirin physician's insert when pegintron is to be used in combination with ribavirin.

Izraēla - ivrits - Ministry of Health

merck sharp & dohme israel ltd - peginterferon alfa 2b 100 mcg / 0.5 ml - powder for solution for injection - peginterferon alfa-2b - peg- intron is indicated for the treatment of adult patients with histologically proven chronic hepatitis c who have elevated transaminases without liver decompensation and who are positive for serum hcv-rna or anti-hcv including naive patients with clinically stable hiv coinfection. the best way to use peg- intron in this indication is in combination with ribavirin. this combination is indicated in naive patients including patients with clinically stable hiv co-infection and in patients who have failed previous treatment with interferon alpha (pegylated or nonpegylated ) and ribavirin combination therapy or interferon alpha monotherapy. interferon monotherapy including peg-intron is indicated mainly in case of intolerance or contraindication to ribavirin. please refer also to the ribavirin physician's insert when pegintron is to be used in combination with ribavirin.